Search
Zastumotide
go.drugbank.com/drugs/DB14926InvestigationalZastumotide is a recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (MAGE-A3 ASCI) also known as astuprotimut-R. … It is under investigation in clinical trial NCT00257738 (0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck).
DYNE-251
go.drugbank.com/drugs/DB18130InvestigationalDYNE-251 is a phosphorodiamidate morpholino oligomer (PMO) conjugated to a fragment antibody (Fab) that binds to the transferrin receptor 1 (TfR1). … It is being investigated for the treatment of Duchenne muscular dystrophy (DMD) in patients who are amenable to exon 51 skipping.
BO-653
go.drugbank.com/drugs/DB19216InvestigationalBO-653 is under investigation in clinical trial NCT00055510 (A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and
BB 21217
go.drugbank.com/drugs/DB17373Investigational21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as [idecabtagene vicleucel] (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP) for
RGX-501
go.drugbank.com/drugs/DB17639InvestigationalIt is being investigated for the treatment of homozygous familial hypercholesterolemia.[L46696] … RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells.
Desoxycortone
go.drugbank.com/drugs/DB15972ExperimentalCategories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, PlainEpicillin
go.drugbank.com/drugs/DB13300ExperimentalCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseCTCE-0214
go.drugbank.com/drugs/DB05934ExperimentalCTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood
Elacridar
go.drugbank.com/drugs/DB04881InvestigationalIn many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline.